UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
英国NICE推荐百济神州的抗癌药物治疗罕见的血癌
- England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ:BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.
- This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales.
- Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study.
- WM is a rare form of B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkin lymphomas. Around 4,000 people are living with WM in the U.K.
- The NICE recommendation states that Brukinsa is considered cost-effective at a threshold of £20,000-30,000 per quality-adjusted life year.
- Also, the European Medicines Agency's Committee for Medicinal Products for Human Use backed Brukinsa approval for marginal zone lymphoma patients who have received at least one prior anti-CD20-based therapy.
- Price Action: BGNE shares closed lower by 1.45% at $154.82 on Monday.
- 英国国家健康与护理卓越研究所(NICE)建议百济神州股份有限公司纳斯达克代码：BGNE)布鲁金萨(Zanubrutinib)治疗至少接受过一种治疗的成年人的Waldenström巨球蛋白血症(WM)，前提是苯达莫司汀和利妥昔单抗也适用。
- NICE的这一决定标志着Brukinsa成为第一种也是唯一一种被推荐在英格兰和威尔士常规使用的WM治疗方法。
- 另请阅读： 百济神州的Brukinsa在白血病研究中的总有效率超过JNJ的Imbrovica.
- WM是一种罕见的B细胞淋巴瘤，只有不到2%的非霍奇金淋巴瘤患者会发生这种淋巴瘤。在英国，大约有4000人与WM一起生活。
- NICE的建议指出，Brukinsa被认为是具有成本效益的，每个质量调整的生命年的门槛为20,000-30,000 GB。
- 此外，欧洲药品管理局的人用药品委员会支持Brukinsa批准边缘地带淋巴瘤患者接受至少一种先前基于CD20的抗治疗。
- 价格行动：周一，BGNE股价收盘下跌1.45%，至154.82美元。